With All Chips On Phase II Antibody Conjugate, CuraGen Eyes Strategic Options
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech’s cash coffers are well stocked, but out-license of GPNMB-targeting cancer drug – or outright sale of the company – could be next.